Brimonidine

Alphagan, Alphagan P, Lumify, Mirvaso, Qoliana (brimonidine) is a small molecule pharmaceutical. Brimonidine was first approved as Alphagan on 1996-09-06. It is used to treat open-angle glaucoma in the USA. It has been approved in Europe to treat skin diseases. The pharmaceutical is active against alpha-2B adrenergic receptor, alpha-2A adrenergic receptor, and alpha-2C adrenergic receptor. Alphagan p's patents are valid until 2031-06-13 (FDA).